Lenalidomide Capsule
Product Images NDC 60219-1718

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 60219-1718). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Lenalidomide Capsules 1)

Chemical structure of lenalidomide. The diagram shows the molecular components and bonds characteristic of the lenalidomide molecule, including a piperidine ring, an amide group, and associated functional groups.*

FDA Label Image

8 (Lenalidomide Capsules 10)

Lenalidomide Capsules 10 mg oral dosage form packaging label from Amneal Pharmaceuticals NY LLC. Label indicates 100 capsules per container, with a warning about potential human birth defects. Capsule shown is half green and half yellow. Includes manufacturer and distributor information, a barcode, and a QR code linking to the medication guide.*

FDA Label Image

9 (Lenalidomide Capsules 11)

Label for Lenalidomide Capsules 15 mg by Amneal Pharmaceuticals NY LLC. The label shows the 15 mg strength with a capsule image, a warning about potential human birth defects, package quantity of 100 capsules, storage instructions, manufacturer information for Amneal Pharmaceuticals Pvt. Ltd., and includes a QR code and barcode.*

FDA Label Image

10 (Lenalidomide Capsules 12)

Lenalidomide Capsules 20 mg packaging label from Amneal Pharmaceuticals NY LLC. The label shows the product name with strength and dosage form, a warning about potential human birth defects, an image of a blue capsule, quantity of 100 capsules, storage instructions, manufacturer information (Amneal Pharmaceuticals Pvt. Ltd., India), and a QR code linking to the medication guide.*

FDA Label Image

11 (Lenalidomide Capsules 13)

Label for Lenalidomide Capsules 25 mg by Amneal Pharmaceuticals NY LLC. The label includes the product name, strength, dosage form, and a warning about the potential for human birth defects. It states the package contains 100 capsules and provides storage instructions, manufacturer details, and a QR code linking to the medication guide.*

FDA Label Image

2 (Lenalidomide Capsules 2)

A Kaplan-Meier survival curve chart depicting progression-free survival probability (%) over time in months for three treatment groups labeled Rd Continuous, Rd18, and MPT. The chart includes hazard ratios with 95% confidence intervals, logrank p-value, and a table displaying the number of subjects at risk at various time points. Survival probabilities and event counts for each group are summarized below the chart.*

FDA Label Image

3 (Lenalidomide Capsules 3)

A survival probability chart depicting overall survival (%) of three groups labeled Rd Continuous, Rd18, and MPT over a period of 72 months. Different line styles distinguish each group, and the chart includes hazard ratios (HR) with confidence intervals (CI) comparing these groups, as well as the number of subjects at risk at various time points along the x-axis (months).*

FDA Label Image

01 (Lenalidomide Capsules 4)

A Kaplan-Meier survival curve comparing progression-free survival (PFS) in months between Lenalidomide and placebo. The y-axis represents the proportion of subjects surviving without progression, and the x-axis shows time in months. Lenalidomide is shown with a blue solid line, and placebo with a red dashed line. The graph includes a table of the number of subjects at risk at various time points and reports PFS events for each group.*

FDA Label Image

02 (Lenalidomide Capsules 5)

A Kaplan-Meier survival curve comparing progression-free survival probabilities over time (in months) between Lenalidomide and placebo groups. The graph shows survival probability on the y-axis and progression-free survival duration on the x-axis with accompanying risk table and hazard ratio statistics below the plot.*

FDA Label Image

4 (Lenalidomide Capsules 6)

A Kaplan-Meier survival curve comparing time to progression (months) between subjects treated with Lenalidomide Capsules/Dexamethasone and those treated with Placebo/Dexamethasone. The y-axis shows the proportion of subjects, ranging from 0 to 100%, and the x-axis shows time up to 30 months. The Lenalidomide group demonstrates a longer time to progression compared to placebo, with statistical significance indicated by a hazard ratio of 0.285 (95% CI 0.210-0.386) and a log-rank p-value < 0.001.*

FDA Label Image

5 (Lenalidomide Capsules 7)

A Kaplan-Meier curve chart illustrating time to progression in months versus proportion of subjects. The graph compares Lenalidomide Capsules/Dexamethasone with Placebo/Dexamethasone, showing differences in progression over about 20 months. Statistical values including hazard ratio (HR) with 95% confidence interval and a Log Rank p-value are visible.*

FDA Label Image

5 (Lenalidomide Capsules 8)

Lenalidomide Capsules 2.5 mg label from Amneal Pharmaceuticals NY LLC. The label shows a teal and white capsule image, states a 100 capsule count, includes a warning about potential for human birth defects, and provides dosage and storage information. It includes an NDC number (60219-1714-2) and a QR code linking to the medication guide.*

FDA Label Image

7 (Lenalidomide Capsules 9)

Packaging label for Lenalidomide Capsules 5 mg by Amneal Pharmaceuticals NY LLC. The label indicates a 100-capsule bottle, with warnings about potential human defects. It includes storage instructions and manufacturer details, as well as barcode and QR code for medication guide access.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.